Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 436.05 Million USD | -23.22% |
| 2022 | 567.93 Million USD | 159.45% |
| 2021 | 218.9 Million USD | 91.17% |
| 2020 | 114.5 Million USD | -76.1% |
| 2019 | 479.12 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 332.79 Million USD | 83.09% |
| 2024 Q1 | 182.29 Million USD | 19.33% |
| 2023 Q2 | 94.01 Million USD | 20.86% |
| 2023 FY | 432.68 Million USD | -23.81% |
| 2023 Q1 | 77.78 Million USD | -63.55% |
| 2023 Q3 | 110.54 Million USD | 17.59% |
| 2023 Q4 | 152.76 Million USD | 38.19% |
| 2022 Q1 | 89.77 Million USD | 76.43% |
| 2022 FY | 567.93 Million USD | 159.45% |
| 2022 Q4 | 213.41 Million USD | 215.53% |
| 2022 Q3 | 67.63 Million USD | -65.69% |
| 2022 Q2 | 197.11 Million USD | 119.56% |
| 2021 Q4 | 50.88 Million USD | -8.31% |
| 2021 Q1 | 266.63 Million USD | 0.0% |
| 2021 Q2 | 247.48 Million USD | -7.18% |
| 2021 Q3 | 55.49 Million USD | -77.58% |
| 2021 FY | 218.9 Million USD | 91.17% |
| 2020 Q2 | 167.22 Million USD | 10.26% |
| 2020 FY | 114.5 Million USD | -76.1% |
| 2020 Q3 | 176.57 Million USD | 5.59% |
| 2020 Q1 | 151.67 Million USD | 12.36% |
| 2019 Q1 | 54.46 Million USD | 0.0% |
| 2019 FY | 479.12 Million USD | 0.0% |
| 2019 Q4 | 134.98 Million USD | 49.23% |
| 2019 Q3 | 90.45 Million USD | -54.59% |
| 2019 Q2 | 199.21 Million USD | 265.76% |
| 2018 Q3 | 54.93 Million USD | 44.13% |
| 2018 Q1 | 83.43 Million USD | 5.24% |
| 2018 Q2 | 38.11 Million USD | -54.32% |
| 2017 Q2 | 25.21 Million USD | 73.95% |
| 2017 Q3 | 39.56 Million USD | 56.9% |
| 2017 Q4 | 79.28 Million USD | 100.37% |
| 2017 Q1 | 14.49 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ADC Therapeutics SA | 233.01 Million USD | -87.134% |
| Alto Neuroscience, Inc. | 37.8 Million USD | -1053.299% |
| Annovis Bio, Inc. | 45.03 Million USD | -868.249% |
| Ginkgo Bioworks Holdings, Inc. | 1.1 Billion USD | 60.659% |
| Nuvation Bio Inc. | 99.82 Million USD | -336.829% |
| Nuvation Bio Inc. | 99.82 Million USD | -336.829% |
| Arcus Biosciences, Inc. | 457 Million USD | 4.584% |
| Theriva Biologics, Inc. | 21.43 Million USD | -1934.674% |
| Zymeworks Inc. | 196.76 Million USD | -121.616% |